Adjuvant pembrolizumab was approved for patients with renalcell carcinoma on the basis of improvements in diseasefree survival observed in the KEYNOTE564 trial. Data on overall survival are needed.
Research findings are summarized in a Quick Take video.
To see the full article, follow this link: https://nej.md/3TVLuKz
#oncology #cancerresearch #clinicaltrials #medicalresearch #nejm